The German pharmaceutical and life sciences company reported first-quarter earnings that topped consensus
Bayer revealed an EPS of €2.59, beating the €2.47 forecast. At the same time, the revenue figures came in at $12.33 billion, higher than the €12 billion initially touted.
The company’s free cash flow plummeted to -€3.23 billion, from last year’s -€793 million. The plunge was caused by the settlement payments for litigations involving its Roundup pesticide.
For the entire 2021, Bayer expects sales to clock between €42 billion and €43 billion., in line with its previous outlook.
After the news hit the wires, Bayer stock price went up almost 5%. Since the beginning of the year, its shares are up 16%.
Sources: investing.com, marketwatch.com
Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.
Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.